Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals — Investor Presentation (March 2020)

33 slides from Sunesis Pharmaceuticals's investor presentation, Mar 18, 2020

  1. Slide 1: Corporate Overview March 2020

    Corporate Overview March 2020

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements, including statements related to the continued development of vecabrutinib (SNS-062) and other product candidates, including the timing and preliminary results of Phase 1b/2 trial of vecabrutinib and the therapeutic potentia

  3. Slide 3: Sunesis Overview

    Sunesis Overview TAK-580: Pan-RAF inhibitor Partnered Programs Vosaroxin: Topo2 inhibitor for AML Partner DOT Therapeutics-1 Denovo Biopharma Preclinical Phase 1 Phase 2 Phase 3 B-Cell Malignancies Vecabrutinib BTK Hematologic/Solid Tumors SNS-510 PDK1 Kinase Inhibitor Pipeline

  4. Slide 4: BTK Inhibition is a Backbone of Therapy for CLL

    BTK Inhibition is a Backbone of Therapy for CLL Imbruvica: first covalent BTK inhibitor approved Imbruvica 2019 sales: >$7B CLL market share leader (across all lines of therapy) GlobalData estimates 2025 sales >$12B Johnson & Johnson and AbbVie annual reports and earnings releases, GlobalData Foreca

  5. Slide 5: Relapse from Ibrutinib Associated with Acquired Resistance Mutations

    Relapse from Ibrutinib Associated with Acquired Resistance Mutations CLL Progression Woyach et al., J Clin Oncol 2017 Scarfo et al. (ERIC), EHA 2018 Quinquenel et al. (FILO), Blood 2019 Landmark Analysis of 308 Ibrutinib-Treated Patients: ~30% Relapsed at 5 years BTK C481x: Most Common Resistance Mu

  6. Slide 6: Vecabrutinib Non-covalent BTK inhibitor

    Vecabrutinib Non-covalent BTK inhibitor

  7. Slide 7: Vecabrutinib BTK Kinase Domain Interaction Differentiated from Ibrutinib

    Vecabrutinib BTK Kinase Domain Interaction Differentiated from Ibrutinib Cys481 vecabrutinib ibrutinib Hinge αC-helix Thr474 (gatekeeper) Activation loop Cys481 Hinge αC-helix Thr474 (gatekeeper) Activation loop Vecabrutinib distinct kinase domain interaction translates into improved selectivity ove

  8. Slide 8: Vecabrutinib - Selective Kinase Inhibitor

    Vecabrutinib - Selective Kinase Inhibitor Highly selective BTK inhibitor with nanomolar potency1 Emerging ITK role in CLL and other indications: Improves T cell number and function2 Contributes to ibrutinib activity in chronic graft-versus-host disease3 Improves activity of anti-CD19 CAR-T cells in

  9. Slide 9: Vecabrutinib Differentiated Kinase Inhibition Profile

    Vecabrutinib Differentiated Kinase Inhibition Profile TEC Family Kinases Inhibition of Other Kinases IC50 (nM) BTK ITK Tec# TXK* BMX* Notable Target Kinases Ibrutinib2 0.5 10.7 78 2.03 0.8 >10 more: EGFR family Acalabrutinib3 5.1 >1000 93 368 46 Selective Zanubrutinib4 0.22 30 1.9 n/a n/a N/A (not p

  10. Slide 10: Vecabrutinib Active in Wild-type and C481S Mutant BTK

    Vecabrutinib Active in Wild-type and C481S Mutant BTK Activity of ibrutinib and acalabrutinib is profoundly affected1-4 Poor PK contributes to resistance in patients with BTK C481 mutations Vecabrutinib active against BTK C481S mutation and induces apoptosis in BTK-dependent lymphoma cell lines1-4 C

  11. Slide 11: Vecabrutinib in B-Cell Malignancies Phase 1b/2 Trial Status and Preliminary Data

    Vecabrutinib in B-Cell Malignancies Phase 1b/2 Trial Status and Preliminary Data

  12. Slide 12: Vecabrutinib Phase 1b/2 Study Design

    Vecabrutinib in B-Cell Malignancies Phase 1b/2 Study Design C 1 25 Phase 1b CLL/SLL, MCL, WM, DLBCL-ABC, FL, MZL ≥ 2 prior regimens, includes BTK inhibitor if approved for the indication Modified 3+3 Design ≥1 Prior Tx* BTK C481x mutation ≥1 Prior Tx* no BTK C481x mutation ≥2 Prior Tx BTK C481x muta

  13. Slide 13: Phase 1b/2 Vecabrutinib in B-Cell Malignancies

    Phase 1b/2 Vecabrutinib in B-Cell Malignancies Currently treating 9 patients across 300 mg, 400 mg, & 500 mg doses 400 mg response assessments completed Initial 500 mg response assessments: 2Q20 5 of 6 patients are on treatment (3 CLL, 2 MCL)

  14. Slide 14: Baseline Characteristics

    Baseline Characteristics Cohorts 1 - 7 All Patients Cohorts 1-7 N=39 Indication 30 CLL 4 MCL, 3 WM, 1 MZL, 1 DLBCL Median age (range) 67 (47- 86) ECOG PS 0 19 (49%) ECOG PS 1 19 (49%) ECOG PS 2 1 (3%) Median prior tx (range) 4 (2-9) ≥1 Chemotherapy 31 (79%) Covalent BTKi 39 (100%) 33 IBR, 6 Acala Ve

  15. Slide 15: Vecabrutinib Very Well Tolerated

    Vecabrutinib Very Well Tolerated TEAEs ≥10% Drug-Related TEAEs ≥5% and Any Drug-Related Grade 3 or 4 TEAE No drug-related Grade 3 or Grade 4 TEAE have been observed at dose levels higher than 50 mg (Cohort 2) No drug-related bleeding, arthralgia, or cardiac AEs have been reported Allan et al., ASH 2

  16. Slide 16: Clinical Activity in Patients with Diverse Poor Prognostic Features

    Clinical Activity in Patients with Diverse Poor Prognostic Features +/- BTK C481S Mutations SD + + + + Dose mg BID Dose mg BID + + + + SD H=hypermutated; SD=stable disease as assessed by investigator; SPD=sum of the product of the diameters; U=unknown or not determined; VAF=variant allelic frequency

  17. Slide 17: Exposure Increased With Dose

    Exposure Increased With Dose: Cycle 1 Day 8 Concentration-Time Profiles C1D8 median Cmin values: 75 ng/mL (Cohort 1), 451 ng/mL (Cohort 2), 873 ng/mL (Cohort 3), 1124 ng/mL (Cohort 4), 1950 ng/mL (Cohort 5), 1530 ng/mL (Cohort 6), 2555 ng/mL (Cohort 7) Linear Scale Log Scale Allan et al., ASH 2019,

  18. Slide 18: Pharmacodynamic Effects: Reductions in Chemokine CCL4

    Pharmacodynamic Effects: Reductions in Chemokine CCL4 N=24 Allan et al., ASH 2019, Sunesis data - Preliminary data as of 16Mar2020

  19. Slide 19: Vecabrutinib Summary

    Vecabrutinib Summary Evidence of clinical activity in covalent BTKi-relapsed patients with and without C481-mutated BTK disease Exposure increased with dose Very well tolerated Currently treating patients across 3 dose levels (300 to 500 mg BID) Additional response assessments in 2Q20

  20. Slide 20: SNS-510 PDK1 inhibitor

    SNS-510 PDK1 inhibitor

  21. Slide 21: Unique Dual PDK1 Inhibition Mechanism of SNS-510

    Unique Dual PDK1 Inhibition Mechanism of SNS-510 PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of AKT, PKC, RSK and SGK families. Cunningham J T , and Ruggero D, Cancer Discovery 2013;3:1099-1102

  22. Slide 22: PDK-1 Alterations in Cancer

    PDK-1 Alterations in Cancer Gagliardi et al, Semin Cancer Biol 2018

  23. Slide 23: SNS-510: Selective Potent Inhibitor of PDK1

    SNS-510: Selective Potent Inhibitor of PDK1 Hansen et al, AACR-NCI-EORTC 2015 ; Sunesis data [SNS-510] nM dephosph-PDK1 phosph-PDK1 PDK1 Inhibition %activity Kinase IC50 nM Phosphorylated PDK1 3.9 Dephosphorylated PDK1 3.1 Kinases with IC50 < 200 nM FLT3 12nM, LCK 25.4 nM, MNK2 39.8 nM, MET 72.3 nM,

  24. Slide 24: SNS-510 Showed Potent Activity Across 320 Cell Lines

    Sensitive and resistant classifications were used in the subsequent analysis by Fisher’s exact test and in the differential mRNA expression analysis SNS-510 Showed Potent Activity Across 320 Cell Lines from Solid Tumor & Hematologic Cancers

  25. Slide 25: Mutated/Deleted CDKN2A Associated With Sensitivity to SNS-510

    Mutated/Deleted CDKN2A Associated With Sensitivity to SNS-510

  26. Slide 26: Mutated/Deleted CDKN2A Cell Lines Show Sensitivity to SNS-510

    Mutated/Deleted CDKN2A Cell Lines from Various Tissues of Origin Show Sensitivity to SNS-510 Ranked distributions show log10 IC50 values for cell lines harboring CDKN2A mutations or deletions. Cell line responses were classified as sensitive (red), resistant (blue), or intermediate (gray). Taverna e

  27. Slide 27: PDK1 Mediates Acquired Resistance to CDK4/6 Inhibition

    PDK1 overexpression in CDK4/6i resistance & sensitivity of CDKN2A mut/del cell lines supportive of SNS-510 combination with CDK4/6i in breast cancer PDK1 Mediates Acquired Resistance to CDK4/6 Inhibition

  28. Slide 28: SNS-510 Antitumor Activity in AML Xenografts

    SNS-510 Antitumor Activity in AML Xenografts MV4-11 FLT3-ITD Driven MOLM-16 FLT3-ITD Independent FLT3-ITD; TP53 and NPM1 WT; MLL-ENL (t4;11) FLT3 and NPM1 WT; TP53, MLL and MTOR mutated Taverna et al., AACR-NCI-EORTC 2019

  29. Slide 29: SNS-510 PDK1 Inhibitor Summary

    SNS-510 PDK1 Inhibitor Summary Broad activity in screen of 320 solid tumor & hematologic cancer cell lines Potential for greater clinical activity than PI3K or AKT inhibitors Inhibits PI-dependent pathways (PI3K/AKT) Inhibits PI-independent pathways (SGK, PKC, IKK, RSK [S6K]) Potential to combine wi

  30. Slide 30: Summary

    Summary

  31. Slide 31: Financial Position and Capitalization

    Financial Position and Capitalization As of 12/31/19, except as indicated 1 As of 3/4/20. Includes common (111.4M) plus preferred as converted (19.7M) Ticker SNSS (NASDAQ) Cash & Equivalents $34.6 million Debt $5.5 million Shares 131.1 million1 Warrants Stock Options 0.2 million 5.2 million Top Shar

  32. Slide 32: Sunesis Highlights

    Sunesis Highlights Vecabrutinib (BTK) Large and rapidly growing market Non-covalent BTK inhibition is validated Initial 500 mg response assessments in 2Q20 SNS-510 (PDK1) First-in-class target with huge market potential Potential synergy with CDK4/6, KRAS G12C, and BCL-2 inhibitors On track for IND

  33. Slide 33: Thank You

    )) SUME SIS | Pharmaceuticals, In. Thank You

Sunesis Pharmaceuticals — Investor Presentation (March 2020) on 6ix